Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
News
The Leukemia & Lymphoma Society Applauds Bipartisan Agreement to Stop Surprise Medical Bills
Patients are now one step closer to breathing a sigh of relief. For too long, they’ve faced the anxiety of knowing that any visit to a healthcare prov…
News
FDA APPROVAL: TREATMENT ADVANCE FOR PATIENTS WITH MULTIPLE MYELOMA
The U.S. Food and Drug Administration (FDA) today announced approval of selinexor (Xpovio®) for adults with multiple myeloma who have had at least one…
News
Collaboration Driving Progress: LLS Forms Alliances with Leading Cancer Institutions and Foundations to Co-Fund nearly $17 million in New Research Grants
As the world confronts a viral pandemic not seen in the past 100 years, the reverberations are being felt across every sector, from healthcare to the …
BioTheryX Presented Trial in Progress at ASH: A Phase I Trial of BTX-A51 in Patients with AML or High-Risk MDS
Chappaqua, N.Y., December 7, 2020 - BioTheryX, Inc., a clinical stage biotechnology company creating new classes of compounds based on multi-kinase in…
Sutro Biopharma Presents Data for STRO-001 for the Treatment of NHL and AML at ASH
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing compa…
Kymera Therapeutics Presents Preclinical Data on IRAKIMiD and STAT3 Programs at ASH
WATERTOWN, Mass., Dec. 07, 2020 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deli…
Affimed Announces Updated AFM13 Clinical Data Presentation at ASH
Heidelberg, Germany, December 7, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their …
Kiadis announces new data at the 2020 ASH Annual Meeting and Exposition
Amsterdam, The Netherlands, December 6, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage…
Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients
December 06, 2020 - FOSTER CITY, Calif. - Gilead Sciences, Inc. (Nasdaq: GILD) today announced updated results from the magrolimab Phase 1b trial. Mag…
Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting
CAMBRIDGE, Mass., Dec. 06, 2020 - Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that two oral presentations and three posters rel…
Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at ASH
SAN DIEGO, Dec. 05, 2020 - Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medi…
New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta® in ZUMA-1 Trial
December 05, 2020 - SANTA MONICA, Calif. - Kite, a Gilead Company (Nasdaq: GILD), today announced four-year follow-up data from the pivotal ZUMA-1 tri…
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
